{"filing":{"accession_number":"0001477932-26-005238","cik":"0001464165","ticker":"BETRF","company_name":"BetterLife Pharma Inc.","form":"6-K","filing_date":"2026-08-24","report_date":"2026-08-24","primary_document":"betrf_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1464165/000147793226005238/betrf_6k.htm"},"events":[{"id":29106,"run_id":26632,"accession_number":"0001477932-26-005238","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The exhibit discloses the appointment of Dr. Mahan Chehrenama, DO, as Chief Medical Officer of BetterLife Pharma in August 2026. This is a material executive appointment to a senior leadership role leading clinical development of the company's lead asset BETR-001 toward an anticipated IND application in Q1 2027. While the disclosure also includes a stock option grant (500,000 shares at $0.285), the principal disclosed action is the appointment itself, making exec_appointment the primary classification. The appointment is material because it brings specialized migraine drug-development expertise to a critical stage of the company's lead program.","company_name":"BetterLife Pharma Inc.","ticker":"BETRF","filing_date":"2026-08-24","form":"6-K","submitted_at":null,"items":[{"id":31270,"accession_number":"0001477932-26-005238","item_number":"EX-99.1","item_title":"betrf_ex991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The exhibit discloses the appointment of Dr. Mahan Chehrenama, DO, as Chief Medical Officer of BetterLife Pharma in August 2026. This is a material executive appointment to a senior leadership role leading clinical development of the company's lead asset BETR-001 toward an anticipated IND application in Q1 2027. While the disclosure also includes a stock option grant (500,000 shares at $0.285), the principal disclosed action is the appointment itself, making exec_appointment the primary classification. The appointment is material because it brings specialized migraine drug-development expertise to a critical stage of the company's lead program.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-24T14:01:39.660468+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31270,"accession_number":"0001477932-26-005238","item_number":"EX-99.1","item_title":"betrf_ex991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The exhibit discloses the appointment of Dr. Mahan Chehrenama, DO, as Chief Medical Officer of BetterLife Pharma in August 2026. This is a material executive appointment to a senior leadership role leading clinical development of the company's lead asset BETR-001 toward an anticipated IND application in Q1 2027. While the disclosure also includes a stock option grant (500,000 shares at $0.285), the principal disclosed action is the appointment itself, making exec_appointment the primary classification. The appointment is material because it brings specialized migraine drug-development expertise to a critical stage of the company's lead program.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-24T14:01:39.660468+00:00","company_name":"BetterLife Pharma Inc.","ticker":"BETRF","filing_date":"2026-08-24"}]}